Chronic Urticaria Drug Pipeline: 28 Assets by Phase

How many chronic urticaria drugs are in each phase of development?

Douglas Insights counts 8 chronic urticaria candidates in Phase III, 29% of the 28 assets in development; Phase II holds 10 and Phase I holds 10.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each chronic urticaria asset appears in exactly one row. The 41 trials still recruiting or running carry 34% of the 121 registered trials in scope.

How many chronic urticaria trials are recruiting patients now?

20 chronic urticaria trials are recruiting patients and 10 more have not started recruiting yet, out of 121 interventional trials in scope; together they make up 25% of the trial base.

Terminated, suspended and withdrawn chronic urticaria trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the chronic urticaria pipeline?

Novartis Pharmaceuticals leads the chronic urticaria pipeline with 2 candidates; the top 5 sponsors hold 21% of the 28 assets, and 27 sponsors run at least one.

Industry sponsors lead 105 of the 121 chronic urticaria trials (87%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the chronic urticaria pipeline?

Mechanism and drug-type classification for the 28 chronic urticaria candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What chronic urticaria trial readouts are coming next?

10 chronic urticaria candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many chronic urticaria readouts fall in each quarter?

14 chronic urticaria candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 6, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most chronic urticaria trials?

United States hosts the most chronic urticaria trials, with sites in 54 of the 121 studies (45%); trials in scope run in 59 countries in all.

A multinational chronic urticaria trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are chronic urticaria drugs being tested?

54 of the 121 chronic urticaria trials (45%) have a site in the United States, 50 (41%) in Europe and 26 (21%) in China; 12 of the 28 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational chronic urticaria trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the chronic urticaria pipeline since the last update?

This is the first edition of the chronic urticaria pipeline count, dated 3 Oct 2026. The next refresh is due by 1 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the chronic urticaria pipeline?

Douglas Insights read 121 interventional trials registered on ClinicalTrials.gov for the conditions "Chronic Urticaria", "Chronic Spontaneous Urticaria" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 28 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the chronic urticaria pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage